Flagship picks Pfefer to lead Kintai, succeeding Tak

Flagship Pioneering has chosen former GSK vaccines executive Guillaume Pfefer to lead portfolio company Kintai, making him the firm’s second hire to take the title of CEO partner.

Pfefer succeeds Paul-Peter Tak, who had led Kintai since its launch. Tak, a former SVP of R&D and chief immunology officer at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), will continue to serve in an advisory role at the Flagship portfolio company; however, he has left his role as venture partner at the firm...